Developments and future clinical outlook of taxane nanomedicines
- 1 May 2017
- journal article
- review article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 253, 137-152
- https://doi.org/10.1016/j.jconrel.2017.03.027
Abstract
No abstract availableKeywords
This publication has 236 references indexed in Scilit:
- Switching the Targeting Pathways of a Therapeutic Antibody by NanodesignAngewandte Chemie-International Edition, 2011
- Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticlesBiomaterials, 2011
- Targeted drug delivery to tumors: Myths, reality and possibilityJournal of Controlled Release, 2011
- Nanonization strategies for poorly water-soluble drugsDrug Discovery Today, 2011
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionCancer Chemotherapy and Pharmacology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered ReleasePharmaceutical Research, 2010
- HPMA copolymers: Origins, early developments, present, and futureAdvanced Drug Delivery Reviews, 2010
- Polymer-drug conjugates: Recent development in clinical oncologyAdvanced Drug Delivery Reviews, 2008
- The shape of things to come: Structural and synthetic studies of taxol and related compoundsPhytochemistry, 2007